Skip to main content
Premium Trial:

Request an Annual Quote

Quanterix Inks Distribution Deals in Asia Pacific Region

NEW YORK (GenomeWeb) – Quanterix has signed two distribution deals to further the reach of its Simoa single molecule analyzer instrument in the Asia Pacific region.

The Lexington, Massachusetts-based company has inked an exclusive distribution agreement for China with Cold Spring Biotech and a non-exclusive agreement for Singapore, Thailand, and Malaysia with Research Instruments.

Financial terms and other details of the agreements were not disclosed.

Taiwan's Cold Spring Biotech said it has offices in Beijing, Shanghai, and Guangzhou, among other cities in China.

Research Instruments is based in Singapore with subsidiaries operating in Thailand and Malaysia. The firm also has distribution agreements with Fluidigm for Singapore and Thailand, and Affymetrix, among others.

Quanterix's Simoa analyzer offers single molecule detection for protein and antigen quantification. The instrument has potential for both research and diagnostic applications.

The company entered the Asian market via Japan with an exclusive distribution agreement with Scrum. In a statement, the firm added that it already has several pending orders in China and that it will continue expanding into the region.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.